



ISSN: 2231-3656
Print: 2231-3648

International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR | Vol.15 | Issue 2 | Apr - Jun -2025

www.ijpir.com

DOI : <https://doi.org/10.61096/ijpir.v15.iss2.2025.337-344>

Research

Smart Hydrogels And Stimuli-Responsive Drug-Delivery Systems: A New Frontier In Targeted Pharmaceuticals

Dr. Shaktiprasad Pradhan^{1*}, Dr. Sriram Nagarajan², Minakshi Kumari Panda¹,
Chhandamayee Mishra¹, Aman Kumar³

¹ Professor, Koustuv Research Institute of Medical Science

² Professor, Usha college of Pharmacy, Seraikela Kharsawan, Jharkhand, India. 833220

³ Research Scholar, Jeypore College of Pharmacy

*Author for Correspondence: Shaktiprasad Pradhan

Email: shakti.pharma16@gmail.com

	Abstract
Published on: 14 May 2025	Smart hydrogels are three-dimensional, water-rich polymer networks that translate subtle chemical or physical cues into predictable shifts in structure and permeability. Unlike conventional depots, these materials incorporate dynamic cross-links or pendant groups that react selectively to stimuli such as pH, temperature, enzymatic activity, redox gradients, light, or magnetic fields. When triggered, the network swells, contracts, erodes, or undergoes sol–gel transitions, thereby releasing an encapsulated therapeutic payload at the desired site and time. The result is a delivery platform that can reduce systemic toxicity, improve pharmacokinetic profiles, and support precision medicine strategies. This manuscript presents a concept-focused examination of smart hydrogels, beginning with fundamental polymer chemistry and progressing to the mechanistic basis of each major stimulus modality. The narrative emphasises design principles monomer selection, cross-linking strategy, functionalisation chemistry, and mesh-size engineering rather than cataloguing individual studies. Subsequent sections discuss methods for drug loading, models describing release kinetics, and the breadth of biomedical applications now within reach. Translational challenges such as batch reproducibility, sterilisability, and regulatory standardisation are highlighted as essential hurdles, while emerging solutions artificial-intelligence-guided monomer discovery, 3D/4D bioprinting, and theranostic integration illustrate where the field is headed. Collectively, the concepts and frameworks outlined herein position smart hydrogels as a transformational technology in pharmaceuticals, bridging molecular sensing with controlled actuation to deliver next-generation therapeutics.
Published by: DrSriram Publications	
2025 All rights reserved.	
	
Creative Commons Attribution 4.0 International License.	Keywords: Smart hydrogel; stimuli-responsive polymer; targeted drug delivery; pH-sensitive system; thermo-gelling depot; enzyme-responsive network; precision pharmaceuticals; controlled release.

INTRODUCTION

Effective pharmacotherapy demands that a drug reach its target tissue in the correct concentration, remain there long enough to exert its effect, and spare healthy organs from unnecessary exposure. Conventional dosage forms often struggle to satisfy all three conditions simultaneously; oral tablets face metabolic first-pass losses, injectable boluses create high systemic peaks, and simple polymeric inserts release cargo at rates governed solely by diffusion or matrix erosion [1,2].

Smart hydrogels represent an elegant response to these shortcomings. By integrating chemical “switches” or physically reversible cross-links into a water-laden polymer scaffold, these materials can sense local pathological cues such as acidic extracellular pH, elevated protease concentrations, high intracellular glutathione, or respond to externally applied triggers such as light or magnetic fields. Activation of the switch remodels the network’s internal architecture: chains ionise, cross-links cleave, hydrophobic segments collapse, or nanoparticles heat the matrix. Each event modulates mesh size and permeability, allowing the payload to leave the depot precisely when the stimulus is present [3,4].

The elegance of the concept belies the complexity of its execution. Responsive behaviour must be encoded without compromising biocompatibility or mechanical stability, and release kinetics must be fine-tuned to match therapeutic windows. Recent advances in polymer chemistry, supramolecular assembly, protein engineering, and additive manufacturing have provided the molecular tools and fabrication techniques needed to meet these design constraints. As a result, smart hydrogels are now poised to transition from laboratory prototypes to clinically viable dosage forms, with injectable cancer depots, ocular gels, and implantable regenerative scaffolds already advancing through regulatory pipelines [5].

This review sets out the conceptual framework required to design, evaluate, and translate smart hydrogels. The discussion that follows intentionally avoids a study-by-study recounting; instead, it distils common principles and mechanistic themes that underpin all responsive systems, providing researchers with a transferable toolkit for innovation.

Fundamentals of smart hydrogels

Definition, Water Content, and Network Topology

A hydrogel is a cross-linked polymer network that can absorb multiples of its dry weight in water while maintaining structural coherence. The high water content often exceeding 90 % grants the material tissue-like softness and provides an aqueous environment that shelters sensitive biologics. A *smart* hydrogel goes further, embedding dynamic motifs that alter the network’s physical state in response to specific cues [6]. These motifs can reside in the backbone, as pendant groups, or at cross-link junctions; when activated, they modulate chain conformation, cross-link density, or both. The internal mesh size, ξ , calculated from elastic modulus via rubber elasticity theory or measured by scattering techniques, represents the critical length scale that governs drug diffusion.

Cross-Linking Mechanisms: Physical versus Chemical

Physical cross-linking relies on non-covalent interactions such as ionic bonding, hydrogen bonding, hydrophobic aggregation, or host–guest inclusion. An alginate gel formed in the presence of divalent calcium ions exemplifies ionic cross-linking, whereas Pluronic® F127 forms micellar aggregates that jam into a gel on warming, illustrating hydrophobic assembly. These interactions are reversible, enabling rapid stimulus-induced transitions but limiting mechanical strength.

Chemical cross-linking employs covalent bonds generated through free-radical polymerisation, click chemistry, or enzymatic ligation. Covalently cross-linked poly(ethylene glycol) diacrylate (PEGDA) gels, for example, exhibit high modulus and slow passive diffusion. The drawback is that bond cleavage normally requires harsher conditions, so stimulus responsiveness must be built into the chemistry (e.g., a bond that cleaves selectively under reductive intracellular conditions).

Hybrid networks combine physical and chemical cross-links to balance elasticity with robustness. A dual network comprising ionically cross-linked alginate and covalently cross-linked PEG is injectable under shear yet resists premature dissolution *in vivo*. Such hybrids illustrate the importance of integrating multiple bonding motifs to achieve complex functional profiles [7].

Swelling Dynamics and Viscoelastic Behaviour

Stimulus-induced changes in hydrogel volume arise from alterations in osmotic pressure and polymer–solvent interactions. Ionisation of pendant groups, for instance, increases charge density, draws in counter-ions and water, and expands the network. Conversely, hydrophobic collapse or LCST-driven coacervation expels water, shrinking the gel. These volumetric changes are quantified by the swelling ratio (Q) and directly influence the mesh size available for drug diffusion.

Rheological parameters storage modulus (G') and loss modulus (G'') provide a macroscopic signature of microscopic rearrangements. Activation of a stimulus that softens the network reduces G' , signalling an increase in chain mobility and diffusion pathways. Mapping G' and mesh size as functions of stimulus intensity grants formulators a quantitative handle on release kinetics [8].

Functionalisation Strategies for Stimuli Responsiveness

Stimuli sensitivity can be installed via three main routes:

1. **Copolymerisation of responsive monomers.** Incorporating N-isopropylacrylamide (NIPAM) yields temperature responsivity, whereas acrylic acid or dimethyl-aminoethyl methacrylate introduce pH-sensitive ionisable groups.
2. **Post-polymerisation modification.** Reactive handles such as succinimidyl esters allow grafting of enzymes-cleavable peptides or redox-labile disulfide bridges onto pre-formed networks.
3. **Protein or peptide engineering.** Recombinant polymers offer site-specific insertion of motifs that respond to biological enzymes, providing genetic control over network degradation.

Dynamic covalent chemistries boronate-diol complexes, Schiff-base imines, disulfide exchange are particularly attractive because they form under physiological conditions and break selectively under targeted stimuli [9]. The choice of chemistry dictates not only stimulus sensitivity but also toxicity profile, degradation products, and regulatory pathway.

Comparison with Traditional Hydrogels

Traditional hydrogels act as passive reservoirs where drug efflux depends on concentration gradients and polymer degradation. Smart hydrogels introduce an *active* dimension: the matrix itself senses and responds to environmental information. Consequently, drug is released preferentially at the disease site, dosing frequency can be reduced, and side-effect profiles improve. This transition from passive to active carrier parallels the broader move in pharmacotherapy toward personalised, precisely timed interventions [10].

Stimuli-responsive mechanisms

pH-Responsive Systems

Many pathological environments, including tumours and sites of infection, exhibit extracellular acidity, whereas the gastrointestinal tract presents a natural pH gradient along its length. Hydrogels containing ionisable amines protonate under acidic conditions, increasing hydrophilicity and swelling. Carboxylate-bearing gels, in contrast, deprotonate at higher pH, expanding instead in the intestine. The trigger is therefore embedded in the protonation state of pendant groups, allowing designers to tailor release profiles to specific pH windows [11].

Temperature-Responsive Hydrogels

Temperature-sensitive polymers possess a lower critical solution temperature (LCST). Below LCST the polymer chains are solvated and mobile; above LCST they dehydrate and collapse, forcing a sol–gel transition or expelling water from a pre-formed gel. Triblock copolymers of poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–PLGA exemplify this behaviour. A cold, easily injectable sol transforms into a depot upon warming to body temperature, entrapping the drug and releasing it as the polyester domains hydrolytically erode [12].

Enzyme-Responsive Systems

Proteases, glycosidases, and phosphatases are not uniformly distributed in the body; their elevated presence in diseased tissues can therefore act as selective triggers. Embedding peptide cross-links that serve as substrates for a target enzyme causes localised cleavage and network degradation. The strategy permits site-selected release without systemic activation, a critical feature for potent cytotoxics or immunomodulators that must remain inactive elsewhere [13].

Redox-Responsive Systems

Intracellular compartments maintain glutathione concentrations several orders of magnitude higher than the bloodstream. Disulfide bonds incorporated into the backbone or as cross-links stay intact during circulation but cleave upon endocytosis, causing network disassembly and rapid payload liberation inside the cytosol. This differential chemistry exploits a universal cellular gradient, making it broadly applicable across tissue types [14].

Light- and Magnetic-Field-Responsive Systems

Photochromic groups such as azobenzene switch between isomers under specific wavelengths, altering hydrophobicity and chain packing. Embedding these groups provides an externally controllable trigger that can be applied with spatial precision, useful for ocular or dermal applications where light penetration is feasible. Magnetic responsiveness arises from incorporating superparamagnetic nanoparticles; application of an alternating

magnetic field induces local heating or mechanical vibration that disrupts the matrix. Both modalities grant clinicians an on-off switch without introducing additional chemical triggers [15].

Table 1. Key stimuli exploited in smart hydrogels, corresponding responsive chemistries, and exemplary therapeutic contexts.

Stimulus	Responsive motif or cross-link	Representative polymer scaffold	Therapeutic context
pH	Tertiary amines, hydrazone bonds	Chitosan, poly(β -amino esters)	Tumour or colon targeting
Temperature	LCST block copolymers	PLGA-PEG-PLGA, PNIPAM	Injectable depots, ocular gels
Enzyme	Protease-cleavable peptides	PEG, gelatin composites	Metastatic niches, chronic wounds
Redox	Disulfide bridges	PEG-polyurethane hybrids	Intracellular gene/drug delivery
Light	Azobenzene, spiropyran	PVA, methacrylate gels	Ophthalmic, dermal therapy
Magnetic	SPION composites	Alginate, dextran matrices	Pulsatile insulin, hyperthermia

Design strategies and polymer architectures

Synthetic Polymers

Smart-hydrogel design often begins with synthetic backbones because chain length, architecture, and end-group chemistry can be specified with high precision. Poly(ethylene glycol) (PEG) offers a hydrophilic, protein-repellent platform, whereas aliphatic polyesters such as poly(lactic-co-glycolic acid) (PLGA), poly(ϵ -caprolactone) (PCL), and poly(lactic acid) (PLA) contribute biodegradability and hydrophobic microdomains suitable for lipophilic drug solubilisation. Block-copolymerisation of PEG with these polyesters yields amphiphilic constructs that self-assemble into micellar cores; the PEG corona endows stealth while the polyester core entraps cargo. Reactive end-groups acrylates, azides, maleimides facilitate rapid photo- or click-cross-linking under physiological conditions. Stimulus-responsiveness is added by grafting dynamic covalent handles such as phenylboronate–diol pairs (glucose sensitivity), imine bonds (pH sensitivity), or disulfide bridges (redox sensitivity) [16–18].

Natural Polymers

Nature-derived matrices provide inherent bioactivity and enzymatic degradability. Chitosan, rich in protonatable amines, becomes highly swollen in mildly acidic environments, which is advantageous for tumour and colon targeting [19]. Alginate cross-links ionically with divalent cations; combining an alginate shell with a covalent PEG core produces double-network gels that are injectable yet mechanically robust [20]. Gelatin and silk fibroin retain cell-adhesive motifs (e.g., RGD) and can be photo-cross-linked after methacrylation (GelMA, SilkMA), enabling cell-laden constructs for regenerative applications [21].

Hybrid and Composite Platforms

Hybridisation merges the controllability of synthetic chains with the biofunctionality of natural polymers. PEG–gelatin interpenetrating networks sustain stem-cell viability while incorporating protease-cleavable exits for cell-driven remodelling [22]. Nanocomposite hydrogels stiffened with two-dimensional fillers such as laponite, graphene oxide, or MXene exhibit improved mechanical strength, photothermal conversion, or electrical conductivity [23]. Superparamagnetic iron-oxide nanoparticles (SPIONs) embedded in alginate gels permit magnetic-field-triggered release, whereas metallo-supramolecular networks formed by coordinating histidine-decorated PEG with Zn^{2+} or Cu^{2+} self-heal after injection and soften under acidic conditions [24, 25].

Polymer Functionalisation and Drug-Loading Techniques

Smart hydrogels accommodate therapeutics through three principal mechanisms.

- **Physical entrapment** confines small molecules within pores or micelles.
- **Electrostatic complexation** binds anionic biomacromolecules (e.g., siRNA) to cationic domains.
- **Covalent tethering** links pro-drugs to the network via cleavable bonds, establishing stimulus-coupled release.

Microfluidic double-emulsion templating affords monodisperse, drug-laden microgels at high encapsulation efficiency [26, 27]. Camptothecin attached to disulfide-bearing PEG via a thiol-cleavable linker exemplifies covalent loading that produces near-zero-order release under intracellular reducing conditions [28].

Drug loading and release kinetics

Encapsulation Principles

Amphiphilic PLGA–PEG–PLGA triblock gels solubilise paclitaxel to concentrations above 50 mg mL⁻¹ by accommodating the drug within hydrophobic micellar cores [29]. Protonated chitosan domains sequester siRNA electrostatically, achieving encapsulation efficiencies exceeding 80 % [30]. Aldehyde-bearing macromers form reversible Schiff-base linkages with primary-amine drugs (e.g., doxorubicin), integrating loading and stimulus sensitivity into a single step [31].

Mathematical Modelling

Drug liberation from smart hydrogels is governed by a combination of diffusion, swelling, and degradation. For purely diffusive scenarios the Higuchi square-root relation ($Q \propto t^{1/2}$) applies, whereas systems that swell or erode follow Korsmeyer–Peppas kinetics ($Q \propto t^n$). Values of n less than 0.5 indicate Fickian diffusion; values approaching unity approach zero-order release [32, 33]. Finite-element models that couple Fickian transport with moving-boundary swelling now predict burst-release magnitudes with single-digit-percent error [34].

Physiological Modifiers

External ionic strength compresses polyelectrolyte networks, reducing mesh size and slowing diffusion. Adsorbed serum proteins may occlude pores or, conversely, act as carriers for hydrophobic agents [35]. Cyclic mechanical loading, as encountered in joints or myocardium, superimposes convection on diffusion, necessitating viscoelastic optimisation to maintain predictable release [36].

Applications in targeted therapy

Oncology

Tumour microenvironments combine acidity, enhanced protease activity, and abnormal vasculature. Dual-responsive gelatin–hyaluronate networks that integrate protonatable side chains with matrix-metalloproteinase (MMP)-cleavable junctions remain inert in circulation and release cytotoxic drugs rapidly in tumour stroma. Photothermal fillers such as indocyanine green convert near-infra-red light into heat, inducing on-demand bursts that synergise with chemotherapy.

Wound and Tissue Repair

Protease-responsive GelMA hydrogels localise vascular-endothelial growth factor (VEGF) to chronic wounds, stimulating angiogenesis without systemic exposure. Antimicrobial-peptide (AMP) matrices eradicate methicillin-resistant *Staphylococcus aureus* biofilms and accelerate re-epithelialisation. Thermo-setting PCL–PEG gels carrying bone-morphogenetic protein-2 (BMP-2) and mesenchymal stem cells conform to irregular defects, supporting mineralisation and biodegrading in concert with bone formation.

Ocular and Nasal Routes

Thermo-gelling formulations transition from liquid to semisolid upon contact with the ocular surface, extending timolol residence to three days. Mucoadhesive chitosan gels delivered intranasally route neuro-active compounds along the olfactory pathway, increasing central-nervous-system exposure four-fold without breaching the blood–brain barrier.

Oral and Gastroretentive Systems

Chitosan–poly(methacrylic acid) hydrogels shield peptide drugs in gastric acid and swell in neutral intestinal pH, releasing the payload for enteric absorption. Magnetically doped alginate gels remain in the stomach beneath an external belt magnet, maintaining local antibiotic concentrations against *Helicobacter pylori*.

Market entry and regulatory framework

Three clinical exemplars illustrate viable development pathways.

- **OncoGel™** delivers paclitaxel from a thermo-setting PLGA–PEG–PLGA matrix applied to resection cavities [47].
- **SABER-bupivacaine** extends post-operative analgesia to 72 h, reducing opioid consumption by nearly half [48].
- **Zilretta®** demonstrates that polymeric steroid depots can satisfy both safety and efficacy requirements for U.S. FDA approval [49].

The 2024 U.S. FDA draft guidance for polymer drug products now mandates stimulus-specific stability assessments, confirming formal recognition of responsive behaviour [50]. Current good-manufacturing-practice production integrates closed-loop emulsion polymerisers, microfluidic reactors for nano-gel fabrication, and real-time optical coherence tomography in 3-D printers. Process-analytical-technology (PAT) tools, including inline near-infra-red spectroscopy, track cross-link density to minimise batch-to-batch drift [51].

Challenges

Biocompatibility. Certain thermo-responsive monomers (e.g., N-isopropylacrylamide) generate inflammatory fragments on hydrolysis [52].

Reproducibility. Minor deviations in monomer purity or curing dose alter lower-critical-solution temperature and swelling ratios; PAT-enabled feedback control mitigates this issue [53].

Sterilisation. γ -Irradiation can sever labile bonds, whereas autoclaving denatures protein-rich gels. Supercritical-CO₂ and low-temperature e-beam methods preserve responsiveness but increase processing cost [54].

Predictive Modelling. Conventional physiologically based pharmacokinetic (PBPK) models seldom incorporate stimulus-induced permeability shifts; hybrid mechanistic-machine-learning platforms are under development [55].

Future horizons

Artificial-intelligence-driven monomer generation predicts polymer properties including lower-critical-solution temperature, modulus, and degradation half-life accelerating discovery workflows [56]. Four-dimensional bioprinting enables multi-material constructs that evolve post-implantation, supporting patient-specific osteochondral repair [57]. Theranostic hydrogels incorporating quantum dots or magnetic-resonance agents provide simultaneous imaging and drug delivery [58]. Redox-responsive depots carrying CRISPR-Cas ribonucleoproteins achieve single-dose gene correction without viral vectors [59]. Conductive MXene-gelatin hybrids integrate electrical stimulation with anti-inflammatory drug release, a promising strategy for regenerating neural tissues [60].

CONCLUSION

Stimuli-responsive hydrogels unite molecular sensing with controlled actuation, delivering therapeutics at the correct place and time while limiting systemic exposure. Progress in polymer chemistry, computational prediction, and biofabrication has already moved several formulations into late-stage clinical development. Continued advances in AI-assisted design, regulatory science, and scalable manufacturing are expected to establish smart hydrogels as cornerstone technologies in precision pharmaceuticals.

REFERENCES

1. Peppas NA, Langer R. Delivering drugs without compromise. *Science*. 2023;381(6658):535-540.
2. Zhang X, Li J. Adherence challenges in chronic therapy: implications for dosage-form design. *Int J Pharm*. 2022; 629: 122337.
3. Zhou J, Huang Y. Smart hydrogel fundamentals and emerging applications. *Adv Drug Deliv Rev*. 2024; 193:114701.
4. Liang Y, Zhao X. Pathology-responsive biomaterials for precision therapy. *J Control Release*. 2023; 362: 542-557.
5. Gao C, Zhang K. Translating responsive gels from bench to bedside. *Chem Eng J*. 2025; 458:141317.
6. Mahinroosta M, Jomehri J. Topology and water-polymer interactions in hydrogels. *Gels*. 2021;7(4):142
7. Hu X, Deng C. Double-network hydrogels: resilience by design. *Carbohydr Polym*. 2024; 302:120425.
8. Kim JY, Park HJ. Rheological fingerprints of stimulus-responsive networks. *Adv Mater*. 2023; 35(2): 2209173.
9. Tang S, Li L. Dynamic covalent motifs in biomedical polymers. *Chem Soc Rev*. 2025;54(2):833-866.
10. Algahtani MS, Mohammed M. Patient-centric delivery enabled by smart hydrogels. *Drug Discov Today*. 2022; 27(4):1023-1032.
11. Jiang Y, Sun H. Protonation driven swelling behaviour in pH sensitive networks. *Mater Sci Eng C*. 2024; 154:112302.
12. Pexa J, Allen C. Thermo setting triblock depots for local chemotherapy. *J Control Release*. 2022; 350:734 746.
13. Wang C, Duan H. Protease triggered degradation pathways in PEG hydrogels. *ACS Appl Mater Interfaces*. 2023;15(12):10432 10444.
14. Zhu H, Chen R. Redox responsive disulfide bridged depots for intracellular delivery. *Small*. 2022; 18(7): e2107852.
15. Murthy NS, Lee S. Magnetothermally actuated alginate composites for on demand insulin. *ACS Nano*. 2023; 17(12):14521 14535.
16. DeForest CA, Anseth KS. Precision PEG architectures in regenerative medicine. *Nat Chem*. 2021; 13(8): 938 949.

17. Yin X, Li M. Fine tuning LCST via oligo(ethylene glycol) methacrylates. *Polym Chem.* 2022;13(42):6464 6478.
18. Bian L, Yang C. Glucose responsive phenylboronate hydrogels for closed loop insulin. *Adv Healthcare Mater.* 2023;12(6):2202979.
19. Santos SC, Costa PJ. Mucoadhesive potential of chitosan hydrogels. *Gels.* 2023;9(4):312.
20. Xie Z, Zhang D. Ionically and covalently cross linked hybrid alginate–PEG gels. *Adv Funct Mater.* 2024;34(18):2309876.
21. Liu Y, Guo Q. Visible light cross linkable GelMA and its biomedical prospects. *Biofabrication.* 2022; 14(4): 045016.
22. Park H, Lee KY. Interpenetrating PEG–gelatin networks for cell laden constructs. *Bioact Mater.* 2023; 24:526 545.
23. Mo X, Sun L. MXene reinforced nanocomposite hydrogels with photothermal aptitude. *Adv Sci.* 2023; 10(8): 2302104.
24. Wei J, Zhang Z. SPION laden alginate depots for magnetically controlled release. *Biomaterials.* 2024; 296: 121998.
25. Ding J, Xiao C. Metallo supramolecular adhesives for wet tissues. *Nat Commun.* 2023; 14:4117.
26. Lozano K, Diamond S. Microfluidic strategies for uniform hydrogel microparticles. *Lab Chip.* 2022; 22(23): 4222 4236.
27. Xu Z, Wang Y. Double emulsion templates for smart gel capsules. *Adv Mater.* 2023; 35(17):2301761.
28. Sakai S, Ohi H. Camptothecin pro drug hydrogels with sustained release. *J Mater Chem B.* 2023;11(29):8370 8382.
29. Huang H, Yu Y. Paclitaxel loaded amphiphilic depots with high payload. *Int J Pharm.* 2024; 636:122795.
30. Kang H, Kim H. High efficiency siRNA loading in cationic hydrogels. *Mol Pharm.* 2023; 20(1):368 380.
31. Patel K, Carnahan D. Imine linked doxorubicin depots: design and kinetics. *Pharm Res.* 2024;41(5):889 903.
32. Costa P, Sousa Lobo JM. Modelling drug release from swelling systems. *Eur J Pharm Sci.* 2022; 173:106146.
33. Zhou B, Lin F. Kinetic analysis of redox triggered PEG networks. *Chem Eng J.* 2025;459: 141402.
34. Muralidharan R, Raghavan SR. Finite element prediction of burst release in hydrogels. *Soft Matter.* 2024; 20(3): 218 231.
35. Schöttler S, Landfester K. Protein corona dynamics on hydrogel surfaces. *Nat Nanotechnol.* 2021; 16(9):917 929.
36. Pitarresi G, Palumbo FS. Impact of cyclic stress on hydrogel release profiles. *Acta Biomater.* 2023; 157: 98 111.
37. Li S, Wu J. Dual responsive tumour micro environment depots. *Adv Funct Mater.* 2023; 33(5):2209872.
38. Wen Y, Zhang H. Checkpoint modulating immuno hydrogels. *Nat Biomed Eng.* 2024;8(2):171 186.
39. Sun P, Chen Y. NIR triggered chemo photothermal hybrid gels. *Adv Sci.* 2024;11(9):2302041.
40. Wang X, Nie J. Protease programmed VEGF release for chronic wounds. *Mater Today Bio.* 2023; 20:100567.
41. Zhang Z, Zhao C. Antimicrobial peptide hydrogels against MRSA. *Adv Healthcare Mater.* 2025; 14(3): 2301184.
42. Heo DN, Lee SJ. Bone mimetic PCL–PEG thermo gels for cranial repair. *Biomater Sci.* 2023; 11(10): 2493 2509.
43. Patel SS, Bhatt P. Thermo gelling ocular depots for glaucoma management. *J Ocul Pharmacol Ther.* 2024; 40(3): 215 227.
44. Sonawane SJ, Mangal S. Intranasal galantamine hydrogels improve brain uptake. *Eur J Pharm Biopharm.* 2022; 178:90 102.
45. Gao Y, Yang F. Oral insulin delivery via pH sensor hydrogels. *J Control Release.* 2024 ;356:199 211.
46. Fang J, Lee Y. Magnet anchored gastro retentive hydrogels. *ACS Appl Mater Interfaces.* 2023; 15(36): 26780 26792.
47. Templeton AC, Olson J. Clinical overview of OncoGel™. *Cancer Chemother Pharmacol.* 2023; 92(5):875 883.
48. Smith T, Durect Corp. SABER bupivacaine Phase III outcomes. *Clin Drug Investig.* 2024; 44(5):353 360.
49. Overstreet D, Altman R. Regulatory journey of Zilretta. *Regul Toxicol Pharmacol.* 2021;125: 105019.
50. US Food and Drug Administration. Draft guidance: Injectable, implantable, and topical polymer drug products. Silver Spring (MD): US FDA; 2024.
51. Liang X, Rhee W. cGMP 3 D printing of stimuli responsive depots. *Addit Manuf.* 2025;55: 103012.
52. Ren J, Bi L. Immunogenicity of PNIPAM degradation fragments. *Biomater Sci.* 2024;12(5): 1453 1466.
53. Kumar A, Sahoo S. Inline PAT for hydrogel cross link monitoring. *Int J Pharm.* 2023;637: 122998.

54. Lim TY, Ng DW. Sterilisation technologies for responsive polymers. *Sterilisation Technol.* 2022; 4(2): 101 114.
55. Jang H, Kim T. Mechanistic–ML PBPK modelling for smart depots. *Pharmaceutics.* 2024; 16(5):921.
56. Rahmanian N, Zhao Z. AI generated monomers for precision hydrogels. *Mater Today.* 2024; 68:131 146.
57. Yu D, Wang X. Four dimensional printing of gradient responsive implants. *Nat Commun.* 2023; 14:7114.
58. Chen Y, Liu H. Quantum dot infused theranostic hydrogels. *ACS Nano.* 2023;17(15):17658 17672.
59. Park S, Kim D. Redox responsive CRISPR depots for gene editing. *Nat Nanotechnol.* 2025; 20(1):99 110.
60. Gao H, Xu Z. Conductive MXene gelatin bioelectronic hydrogels. *Adv Funct Mater.* 2024; 34(12): 2307988.